Article
Comparison of the Kinase Profile of Midostaurin (Rydapt) with That of Its Predominant Metabolites and the Potential Relevance of Some Newly Identified Targets to Leukemia Therapy.
Biochemistry - 25 Sept 2018
Manley Paul W, Caravatti Giorgio, Furet Pascal, Roesel Johannes, Tran Phi, Wagner Trixie, Wartmann Markus
Abstract excerpt
The multitargeted protein kinase inhibitor midostaurin is approved for the treatment of both newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and KIT-driven advanced systemic mastocytosis. AML is a heterogeneous malignancy, and investigational drugs targeting FLT3 have shown disparate effects in patients with FLT3-mutated AML, probably as a result of their inhibiting different targets and pathways at the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.